A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: Factoring in new trials and meta-analysis data

American Heart Journal

Volumn 149, Issue 4 SUPPL., 2005, Pages

  Topol, Eric J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PYRIDINE DERIVATIVE;

ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY HEMODYNAMICS; DISEASE SEVERITY; DRUG INDICATION; HEALTH CARE MANAGEMENT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; MEDICAL SOCIETY; META ANALYSIS; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 17444387832     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.02.024     Document Type: Article

References (25)

1. P. Theroux, H. Ouimet, and J. McCans Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1988 1105 1111
2. A. Oler, M.A. Whooley, and J. Oler Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis JAMA 276 1996 811 815
3. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol 36 2000 970 1062
4. S. Kaul, and P.K. Shah Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? JACC 35 2000 1699 1712
5. J.W. Eikelboom, S.S. Anand, and K. Malmberg Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST-elevation: A meta-analysis Lancet 355 2000 1936 1942
6. E.M. Antman, M. Cohen, and D. Radley Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI IIB-ESSENCE meta-analysis Circulation 100 1999 1602 1608
7. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Summary article Circulation 106 2002 1893 1900
8. M. Roffi, D.P. Chew, and D. Mukherjee Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: Gradient of benefit related to revascularization strategy Eur Heart J 23 2002 1441 1448
9. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
10. The TACTICS-TIMI 18 Investigators Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
11. F.J. Neumann, A. Kastrati, and P. Murray Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: A randomized controlled (ISAR-COOL) trial JAMA 290 2003 1593 1599
12. The SYNERGY Trial Investigators Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
13. M.A. Blazing, J.A. de Lemos, and H.D. White Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial JAMA 292 2004 55 64
14. J.L. Petersen, K.W. Mahaffey, and V. Hasselblad Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes JAMA 292 2004 89 96
15. E. Boersma, R. Harrington, and D. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
16. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452
17. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB Trial Circulation 100 1999 1593 1601
18. D.A. Morrow, E.M. Antman, and M. Tanasijevic Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-IIB substudy J Am Coll Cardiol 36 2000 1812 1817
19. Harris G. 2 cancer drugs, no comparative data. The New York Times. February 26, 2004:C, 1.
20. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
21. E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary intervention N Engl J Med 344 2001 1888 1894
22. C.P. Cannon, E. Braunwald, and C.H. McCabe Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
23. S.G. Goodman, D. Fitchett, and P.W. Armstrong Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Circulation 107 2003 238 244
24. M. Cohen, P. Theroux, and S. Borzak Randomized, double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study Am Heart J 144 2002 470 477
25. D.B. Mark, R.A. Harrington, and A.M. Lincoff Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide with non-ST-elevation acute coronary syndromes Circulation 101 2000 366 371